Between 2008 and 2013, the landscape of therapeutic areas shifted significantly among major pharmaceutical companies. Cardiovascular medicine, once the top revenue area for several firms, saw its dominance wane, with only AstraZeneca and Sanofi–Aventis remaining leaders by 2013. In contrast, oncology emerged as a significant revenue driver, particularly for Roche and Novartis; Roche’s oncology sales are projected to increase from $17.2 billion to $25.9 billion, driven by key drugs like Avastin, while Novartis anticipates a growth from $4.9 billion to $5.9 billion, largely thanks to Glivec. Additionally, the metabolic therapeutic area is poised for the highest growth rate at 11% CAGR, surpassing other areas, while declines in antihypertensives and antibiotics indicate a shifting focus in the industry. By 2014, immunology is expected to become the second highest revenue contributor, overtaking cardiovascular medicine.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.nature.com/articles/nrd2986
